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Abstract
Treatment 2.0 is an initiative launched by UNAIDS and WHO in 2011 to catalyze the next phase 
of treatment scale-up for HIV. The initiative defines strategic activities in 5 key areas, drugs, 
diagnostics, commodity costs, service delivery and community engagement in an effort to simplify 
treatment, expand access and maximize program efficiency. For adults, many of these activities 
have already been turned into treatment policies. The recent WHO recommendation to use a 
universal first line regimen regardless of gender, pregnancy and TB status is a treatment 
simplification very much in line with Treatment 2.0. But despite that fact that Treatment 2.0 
encompasses all people living with HIV, we have not seen the same evolution in policy 
development for children. In this paper we discuss how Treatment 2.0 principles can be adapted 
for the pediatric population. There are several intrinsic challenges. The need for distinct treatment 
regimens in children of different ages makes it hard to define a one size fits all approach. In 
addition, the fact that many providers are reluctant to treat children without the advice of 
specialists can hamper decentralization of service delivery. But at the same time, there are 
opportunities that can be availed now and in the future to scale up pediatric treatment along the 
lines of Treatment 2.0. We examine each of the five pillars of Treatment 2.0 from a pediatric 
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perspective and present eight specific action points that would result in simplification of pediatric 
treatment and scale up of HIV services for children.
Introduction
Despite successes in the prevention of mother-to-child transmission (MTCT), about 900 
children become infected with HIV each day, 90% in sub-Saharan Africa. Without 
antiretroviral treatment (ART), only half of all HIV-infected children survive to age 2 [1,2]. 
However, as of 2011, it is estimated that of the 2 million children throughout the world in 
need of ART, only one in three are receiving it, well below the estimated 58% for adults [3]. 
Several factors contribute to this treatment gap. To start with, access to timely early infant 
diagnosis (EID) is limited. Of the 22 priority countries in the Global Plan to Eliminate 
MTCT, four have been able to reach EID coverage of 60%, but globally only 30–35% of 
HIV-exposed infants (HEIs) have access to EID in the first 2 months of life [3]. Moreover, 
access to diagnosis and identifying a child as infected does not translate to ART access. 
Linkages between EID services [usually within prevention of mother-to-child transmission 
(PMTCT) programs] and ART services are very weak, resulting in high loss-to-follow-up 
and delayed treatment initiation (see Retention and Linkage to care article in this series) [4]. 
Apart from EID, there are few opportunities for HIV testing in children and adolescents 
whether infected perinatally or through behavioral risks, and so HIV infection often goes 
unrecognized until late in the course of illness when mortality is high [5]. Even after the 
ambitious goal of eliminating new infections in children is achieved, there will still be 
millions of children living with HIV who need care. Interventions to increase access to HIV 
diagnosis and treatment for children and adolescents are, and will continue to be, urgently 
needed.
In 2011, the WHO and UNAIDS launched the Treatment 2.0 Initiative which aims to 
expand treatment, improve efficiency and ensure sustainability of the global response to 
HIV for both adults and children. Treatment 2.0 comprises five key pillars: simplification of 
ART regimens and harmonization of regimens across age groups; access to point of care 
(PoC) diagnosis and monitoring; reduced costs of treatment; service delivery adapted to the 
needs of the population and community mobilization [6]. The newly published WHO 
Consolidated ARV guidelines, promote a Treatment 2.0 approach for adults. ART choices 
are simplified to two preferred once-daily regimens, and the approach to treatment is 
harmonized across diverse adult populations [7]. However, the situation for children is more 
complex. The choice of treatment is partly determined by age, and several different 
regimens are recommended because of limited pediatric data to compare one regimen 
against another and safety concerns with some drugs in younger children. At the same time 
the new guidance does make some recommendations (such as universal access to ART for 
all children <5 years), which are more in line with the intent of Treatment 2.0 for children.
In this paper, we discuss what elements are needed for developing a Treatment 2.0 strategy 
for children across each of the 5 pillars.
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Pillar 1: antiretroviral drugs and regimens
The current situation
The 2013 WHO guidelines call for different ART regimens in children under and over three, 
based on clinical trial data which show that protease inhibitor based ART with lopinavir/
ritonavir (LPVr) is associated with better outcomes than nonnucleoside reverse transcriptase 
inhibitor (NNRTI) based ART in children under 3 years of age [7,8]. However, in practice, 
the current LPVr formulation (a liquid that requires cold chain transport, is poorly palatable 
and contains 42% alcohol and 15% propylene glycol) is very difficult for programs in 
resource-limited settings to use. In addition, LPV/r solution is not recommended for 
neonates before a gestational age of 42 weeks and a postnatal age of at least 14 days [9]. The 
anticipated LPV/r granule formulation will address some of the challenges associated with 
the liquid, and one manufacturer has already filed dossiers with the US Food and Drug 
Administration (FDA). This granule formulation feeds into the work being done on modular 
fixed-dose sachets or capsules that contain nucleoside reverse transcriptase inhibitors 
(NRTIs) combined with LPV/r- a potentially valuable approach to simplifying pediatric HIV 
treatment in line with the principles of Treatment 2.0 [10].
Looking to the future
Pediatric formulations that offer for children what is available for adults that is, the 
convenience of well tolerated, once-a-day regimens in fixed-dose combinations (FDCs), are 
urgently needed. The ideal situation would be one in which the preferred pediatric regimens 
are the same as the preferred adult regimens. At present however, this is not possible. Adult 
preferred regimens all contain tenofovir (TDF), which although approved for use in children 
remains controversial due to safety concerns and the need to monitor for bone toxicity [11]. 
As a result, WHO guidelines recommend TDF-based ART only as an alternative option, for 
children between 3 and 10 years of age. National programs may therefore be reluctant to 
adopt the use of TDF in children, and manufacturers reluctant to make pediatric TDF-
containing FDCs because of low demand. More data on the safety of TDF in young children 
is needed in order to encourage uptake.
Dolutegravir (DLG), an integrase inhibitor, was recently approved by FDA for adults and 
children age 12 and over [12]. DLG in combination with two once daily NRTIs (such as 
TDF, abacavir (ABC), lamivudine (3TC) or emtricitabine (FTC)) may offer a highly potent 
and well tolerated first-line treatment for both adults and children. Adult studies have shown 
the drug to be effective and well tolerated, and clinical trials of DLG in children are under 
way [13]. If DLG-based regimens are effective and well tolerated in both infants as well as 
older children, there is a possibility that future iterations of the WHO guidelines could 
recommend a single DLG-based regimen for all children and adults, thus simplifying 
implementation and coalescing demand.
Securing the pediatric antiretroviral market
Demand for pediatric ARVs is significantly smaller than that for adults, and with the 
increasing focus on elimination of new HIV infections among children, there is an 
assumption that the pediatric ARV market will dwindle [14]. Although this may be true in 
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the long term, in the short to medium term, there is room for growth. Recent data from the 
22 countries that are part of the Global Plan suggest that only 34% of children in need 
receive ART (half of the adult rate), and children account for only 7% of all individuals on 
ART (Fig. 1). If universal access was achieved, pediatric ARV volumes would increase 
three-fold [15]. Estimates for the growth of the pediatric ARV market suggest that at the 
very least, demand will double over the next 4 years (Fig. 2).
Despite this growth potential, the pediatric ARV marketplace is fragile. The commercial life 
span of pediatric ARV formulations is short because of the rapid pace at which clinical 
recommendations evolve. At the same time, there is pressure to keep prices low which 
means that manufacturers struggle to recover their investment. Between 2006 and 2009, a 
large portfolio of child friendly ARV formulations were developed and brought to market, 
but now many of these are often unavailable because of insufficient demand to sustain batch 
production. The problem of short life span is compounded by market fragmentation. The 
spread of formulations across different regimens and age/weight bands means that each 
product becomes a low-volume product. WHO guidelines provide recommendations on the 
drug regimens to be used for ART in children. However, other than promoting the use of 
FDCs, they do not offer guidance on product selection.
In 2011, The Inter-Agency Task Team on prevention and treatment of HIV infection in 
pregnant women, mothers and their children (IATT) released recommendations on pediatric 
ARV product selection for national uptake. This is a list of 41 pediatric products, which are 
divided into ‘optimal’, ‘for limited use’ and ‘nonessential’ formulations [16]. Of the 41 
products reviewed by the IATT, 15 formulations are listed as ‘optimal’, 11 as ‘limited use’ 
to allow transition to optimal products and 13 as ‘nonessential.’
Products were selected as optimal based on the principles of the WHO Essential Medicines 
List for Children. Since the IATT formulary was published in 2011 there has been a decline 
in procurement of limited use and nonessential products. As we look towards implementing 
future Treatment 2.0 options for children, consolidation of pediatric ARV demand around a 
minimal set of optimal products is essential to maintain high product volumes and ensure 
that manufacturers remain invested in pediatric formulation development. A revision of the 
IATT formulary is expected in 2013.
Pillar 2: diagnostics
Improved access to laboratory testing for HIV – especiallytopoint-of-care (PoC) and other 
simplified technologies, is necessary for ART scale-up. For older children (>18 months), 
testing needs are fully harmonized with adults [7]. Diagnosis can be made using the same 
rapid HIV-antibody tests, and now that the WHO guidelines have removed the need for CD4 
percentages in children, immunological staging can be done using the same CD4 absolute 
count assays. For toxicity monitoring, all patients regardless of age, need access to the same 
hematology and chemistry tests – although interpretation of results may differ according to 
age-related norms. The one critical exception is EID. This can only be done using assays to 
detect viral nucleic acids (DNA, RNA or total nucleic acid) or viral proteins (p24antigen). 
These assays are technologically complex and typically only available at a few laboratories 
in each country [17]. And yet access to EID is absolutely essential to identify and treat 
Essajee et al. Page 4
AIDS. Author manuscript; available in PMC 2015 December 17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
children less than 18 months who have the highest mortality of all individuals with HIV (see 
EID article in this series).
Transport of dried blood spot specimens (which are easy to collect, safe to transport and 
stable at room temperature), has enabled significant scale up of EID services by linking a 
small number of central laboratories to a large number of sample collection sites at low-level 
health facilities, but needs remain [18,19]. Currently, only 30–35% of all HEI have access to 
timely diagnosis in the first 2 months of life [3]. Furthermore, delays in the return of results 
are common and sometimes exceed several months contributing to low retention and high 
mortality [20,21]. Use of SMS printers to facilitate EID results return has significantly 
improved turnaround time and should be implemented widely, but there is an urgent need to 
find innovative ways to close the access gap [22].
Emerging PoC platforms for EID provide an alternative to centralized testing that makes 
EID testing feasible even in primary health facilities or mobile clinics [23–25]. These PoC 
tests are expected to be simple to use (including by nonlaboratory staff) and can deliver 
rapid results (within 2 h). Some PoC platforms have built-in wireless networking capacity, 
so that test information including where the test was done and what the result was, can be 
uploaded instantly into a remote database. As yet, no PoC EID test is available 
commercially, but use of PoC might improve health outcomes in several ways:
1. Access to EID would likely increase – especially for remote, rural or hard-to-teach 
communities
2. ‘While-you-wait’ results may save time and money for patients, increase efficiency 
due to fewer ‘wasted’ tests that are never collected, reduce loss-to-follow-up and 
improve early ART initiation rates
3. PoC instruments can be placed at any entry point within a facility – for example 
EID testing can be brought to the labor ward, enabling identification of HIV-
infected infants at birth
4. PoC technologies facilitate task-sharing, allowing work load and resources to be re-
distributed and health facilities to become more self-sufficient
5. Automated data collection will enable sophisticated real-time mapping of tests used 
and results obtained
Strengthening centralized EID and establishing PoC EID are not mutually exclusive but 
rather complementary strategies to achieve the goals of Treatment 2.0 for children. 
Countries will need to strike a balance between these two approaches recognizing the 
relative benefits of each [26]. For example, centralized testing may be better than PoC for 
large facilities which have high sample volumes, optimized turnaround time and already 
high retention rates. Conversely, PoC may be preferable in smaller clinics in which sample 
transport is costly and unreliable and retention rates are low. Implementation of PoC EID 
tests may require revision of the testing algorithm to define for example how to confirm 
positive PoC test results before treatment is initiated" confirmatory.
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Virologic testing technologies whether laboratory-based or PoC are increasingly moving 
towards a single platform for both infant diagnosis and viral load monitoring [23]. This will 
ensure that as viral load testing becomes the norm for ART monitoring, access to EID is 
automatically expanded to a greater numbers of sites. Laboratory services in general face 
systemic challenges including poor supply chain management of reagents, insufficient 
maintenance of equipment, frequent personnel turnover and inadequate quality assurance 
[27]. Even as PoC tests are rolled out, it is important to maintain a strong laboratory 
infrastructure. A comprehensive Treatment 2.0 laboratory strategy for children should 
include general laboratory systems strengthening, optimization of centralized testing and 
appropriate and selective deployment of decentralized PoC testing to provide high quality 
testing services to all children in need.
Pillar 3: reducing costs
On a dosage basis, prices of pediatric ARV products tend to be higher than their adult 
equivalents (See Costing article in this series). Research on pediatric ARV pricing trends 
and cost drivers is limited but higher pricing per mg of drug is typically attributed to fixed 
costs such as packaging and the need for more costly manufacturing technologies to produce 
the formulations necessary to address the challenges of administering ARVs to children such 
as syrups or sprinkles [28–30]. Funding from UNITAID provided over $317 million from 
2006 to 2011to catalyse growth in pediatric HIV commodities; the Global Fund and 
PEPFAR have also made significant investments in both EID services and delivery of 
pediatric ART [31]. However, the global sum of donor support for HIV has remained 
essentially unchanged since 2008 [32]. As a result, the pressure on National Programs to do 
more with the same resources will increase. The challenge for program managers is two-
fold: How can budgets support a doubling or trebling of pediatric patients in the short-term 
to fill current treatment gaps and what innovative pricing mechanisms are available to 
sustain that level of service; and once demand goes down as infections are prevented, how 
will a declining market affect pricing and supply?
A healthy market with a range of comparable competitor prices will find an equilibrium that 
provides a profitable business for suppliers and value to consumers. In such a market, 
volume is a negotiating lever for buyers, enabling them to pressure suppliers to drive prices 
down. An example is the generic first line ARV drug market, where major funders/buyers 
such as PEPFAR, the Global Fund and the Government of South Africa – with important 
support from market influencers such as WHO, UNAIDS, USFDA, UNICEF and CHAI, 
have driven prices for adult treatment from over $10 000 per person per year in 2000 down 
to $120 to $150 [28,30]. Premium products such as second-line ARVs, are niche markets but 
still profitable for some suppliers as they command higher prices due to difficulty of 
manufacture and low volumes.
In the absence of policy action, pediatric ARVs may acquire the characteristics of premium 
products with few suppliers and increasing prices. Currently, two essential pediatric ARV 
products have only one quality-certified manufacturer highlighting the difficulty in engaging 
suppliers in this market. Furthermore, fragmented demand across more than 100 countries, 
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many with very small order volumes, affects supply security – the on-going availability of 
products at affordable prices.
Treatment 2.0 concepts of demand consolidation around a limited set of products and pooled 
procurement across countries may help to control prices and ensure supply security, while 
still providing a commercial return to suppliers [33–35]. The success of the UNITAID 
Pediatric Program illustrates the value of both these strategies. Pooled volumes across many 
countries and consolidated demand around a small number of FDCs (rather than multiple 
syrup formulations) resulted in more accurate global demand forecasting and predictable 
orders, which enabled suppliers to plan production and offer both lower prices and 
consistent supply. As of 2011, a leading pediatric regimen cost US$130 per child per year, 
down from US$252 in 2006 [31]. Pricing transparency via mechanisms such as the WHO 
Global Price Reporting Mechanism is a key ingredient for success [36].
In the longer term, the HIV-infected pediatric population will decline due to reduced 
mother-to-child transmission and as infected children grow into adulthood. It may become 
necessary to explore further options to sustain the pediatric market, such as global 
consolidation of orders and supply channels or an element of premium pricing to encourage 
suppliers to stay in a less attractive business. This potential increase in the unit cost of 
pediatric ARVs will need to be recognized and planned for by funders and international 
agencies to ensure future availability. In addition, the global community may need to 
encourage or negotiate with manufacturers to either subsidize or donate pediatric ARVs to 
secure access.
In the meantime, actions taken by countries in-line with Treatment 2.0 recommended 
policies can promote and secure pricing today and in the near-term, enabling countries to 
increase value for money, further scale-up the number of children accessing treatment and 
stabilize the pediatric ARV market, incentivizing suppliers to invest and innovate further to 
develop clinically needed products.
Pillar 4: service delivery
Optimizing HIV service delivery is a key element of the Treatment 2.0 framework. Pediatric 
HIV services are delivered along the spectrum of care, from diagnosis, through treatment, to 
retention. A rift at any point impacts the effectiveness of the whole, but at present these 
elements are poorly connected. Diagnosis of HIV in infants and children takes place in 
several settings, including primary care and Maternal Child Health (MCH) clinics (See 
UNICEF article in this series). By contrast, care and treatment of HIV is typically only 
available in secondary and tertiary centers at ART clinics, which are mainly focused on 
adults with small numbers of children on treatment. In most Lower Middle Income 
Countries (LMICs), at least three different programs – ART services, Sexual and 
Reproductive Health and MCH programs – are involved in the health sector response to 
HIV. Frequently, the required political commitment to ensure that they are coordinated to 
achieve an effective integrated service is lacking. In addition, many women relocate to their 
maternal homes for delivery so there may be a geographical disconnect between sites where 
mothers and children are diagnosed, and where they need to come for ongoing treatment and 
care. The multitude of service delivery locations that a caregiver must negotiate belies the 
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fact that HIV infection is a family issue; children mostly acquire it from their mothers, and 
many women or men acquire it from their partners. Where there is one index case, several 
members of the family may be in need of HIV services.
For HIV-infected women and children other types of health services are also needed, such as 
antenatal care (ANC), and immunizations (Fig. 3). Nutrition support and promotion of breast 
feeding is especially important, as healthy infant feeding practices play a major role in the 
survival of both HIV-exposed and infected children (see article on infant feeding in this 
series). Fragmentation of services places a significant burden on families and often results in 
loss to follow-up, but it also poses challenges for the program. When service delivery is 
fragmented, stock-outs of drugs and diagnostics are more likely and it is more difficult to 
collect and record program data.
One potential solution is to co-locate services by decentralizing ART to primary care 
facilities - a practice that is now formally recommended by WHO. This is now common for 
adults, but decentralization of pediatric care has lagged behind for several reasons including 
the limited number of health workers trained to provide pediatric HIV care, the lack of 
pediatric diagnostics and the need to stock pharmacies with many additional formulations. 
The lack of trained providers is especially important as children are often perceived as ‘too 
complicated’ and difficult to treat. Some pioneer programs have overcome these challenges 
and demonstrated excellent outcomes when pediatric HIV care was decentralized to primary 
care settings in a family care approach encouraging providers and clients to bring children 
into care [37–44] (Fig. 4). A large study performed in five sub-Saharan African countries 
showed that pediatric ART coverage increased and there was a suggestion of reduced 
mortality and improved retention in care when services were decentralized [39]. Further, a 
recent systematic review found that outcomes of ART care when provided to children by 
nurses was equivalent to that provided by doctors and specialised staff, at least for children 
who are not critically ill [40].
Service models for decentralization and integration may vary depending on several factors, 
including the availability of human and other resources and the prevalence of HIV. In high 
burden settings, integration of interventions for pediatric HIV diagnosis and care into MCH 
services such as immunization and well child visits should be actively promoted. By 
contrast, in low-burden settings, sparsely populated areas will have very few pediatric HIV 
clients and integration of pediatric HIV care across the entire health service may 
compromise the quality of care since some providers will have very little experience with 
HIV-infected or exposed children. It may be more appropriate to adopt a hybrid model 
where services are decentralized to a certain point, but in remote or rural communities, 
providers are trained how to recognize and diagnose HIV in children, and then refer them to 
regional or central facilities for more specialized services.
Because of the paucity of pediatricians in most developing countries, task sharing must 
accompany decentralization and integration of pediatric HIV care and treatment. Several 
countries such as South Africa and Swaziland provide formal training and certification to 
nurses to initiate and manage ART. These training programs have been modified to include 
pediatric HIV. The WHO Integrated Management of Childhood Illness (IMCI) training 
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materials now include a pediatric HIV component and Tanzania, Zambia and Zimbabwe are 
implementing IMCI-based learning approaches for pediatric HIV, which combine face-to-
face with distant learning modules in order to reach more providers [45]. Pediatric HIV 
training can be combined with interventions such as mentoring and site supervision and 
providing access to specialist providers for consultation in order to ensure that service 
quality is maintained. Although full versions of national pediatric HIV guidelines should be 
available as a resource in ART clinics that serve children, these documents are often too 
large and complex for the needs of the front-line primary care health worker managing 
children with HIV along-side several other clinical responsibilities. A smaller ‘pocket 
reference’, designed to be carried by health workers, which has the clinical essentials 
summarized can improve service delivery. Other job-aides such as testing algorithms, dosing 
tables and ART eligibility checklists can be produced in the form of desk charts or wall 
posters to reinforce good pediatric practice.
Pillar 5: involving our communities
Involving the community in the rollout of HIV services is recognized as an essential 
determinant of acceptability and serves as a model for other public health interventions. 
Traditional roles such as expert clients or peer counselors have expanded to wider and more 
complex participation, including the full engagement of people living with HIV (PLHIV) in 
decision-making processes. Global networks of PLHIV [46,47], are now represented in 
national and international fora and in the recent WHO guidelines, HIV program managers 
are recommended to include civil society stakeholders in all aspects of planning and service 
delivery [7]. However, involvement of the community in pediatric care has not been as 
comprehensive as for adults and pregnant women.
There are some successful models such as the Zvandiri Programme, in Zimbabwe founded 
in 2004 with the goal of providing psychosocial support to HIV-infected children and 
adolescents through a community-led support network [48,49]. The program is linked to 
ART centers and seeks to promote adherence and well being by offering life skills training, 
outreach to children who have been lost to follow-up and mental health counseling. Zvandiri 
reaches over 20 communities and has demonstrated retention rates of over 85%.
Zimbabwe’s PlayCenter Program is another example [50]. These are rural community 
centers, staffed by health workers and volunteers. They provide health, nutritional, 
psychosocial support and a play space for HIV-infected and -affected young children who 
are identified by community mobilizers. A new initiative now also offers mother-baby 
support groups for young mothers
While these examples of community engagement are encouraging and often extraordinary, 
they remain limited by scale and scope. In order to fully harness the strengths of the 
community in supporting children with HIV, community initiatives must form part of the 
national response and should be integrated with similar interventions for adults and pregnant 
women. At the international level, global PLHIV alliances should advocate for this type of 
expansion and integration as part of their mandate. At the country level, National Programs 
should support existing community organizations to identify locally appropriate ways of 
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incorporating child and adolescent focused initiatives into their work. It is essential to 
involve HIV-affected children and youth in this process. Adult community members – 
especially those with specific professional skills, are important but inclusion of the young 
people who will access such initiatives is equally so. For example, HIV-infected adolescents 
who have received training in counselling, are uniquely suited to provide support to their 
peers in order to enhance retention and adherence. Selected proposed interventions for 
community participation and other specific loci for integration are identified as follows:
1. Building off existing programs for community PMTCT support to create linkages 
between EID, well child and pediatric ART services in order to minimize loss to 
follow up of mothers and infants across the PMTCT cascade [51].
2. Raising community awareness around case identification and PITC for infants, 
children and adolescents.
3. Providing community-based diagnosis of children and adolescents.
4. Expanding models of community adherence support such as self-forming groups of 
PLHIV to refill joint ARV prescriptions to address the needs of children and 
adolescents as well as adults [52].
5. Peer support programs expanded to HIV-affected youth.
As child and adolescent community initiatives expand, two important challenges must be 
addressed to ensure long-term success. The first relates to the sustainability of community 
interventions, which generally are poorly institutionalized and funded by donor grants rather 
than national budgets. In some cases, this has led to a lack of continuity and a perception 
among beneficiaries that such interventions are inevitably short-lived. Consistency and 
quality are critical elements to maintain in order for patients to value a community service 
and these can be best ensured when such services are locally managed, nationally owned and 
publicly funded. Health planners at national level should develop innovative approaches to 
provide support for proven community interventions and mainstream them into the health 
system.
The second challenge is that many community interventions still depend on voluntary 
unpaid work, which is disempowering and diminishes the valuable contribution of PLHIV to 
the program. This is especially true for Expert Client programs in which PLHIV who work 
with ART programs often receive no financial support or a minimal monthly stipend. Where 
programs provide a salary, outcomes are excellent. The Partners in Health Rwanda 
Community-HIV program, which uses lay community health workers to provide directly 
observed-therapy and other services has demonstrated long-term improvements in both 
retention (>90%) and mortality (<6%) on ART [53]. The Paediatric AIDS Treatment for 
Africa (PATA) expert client initiative supports 200 dedicated child focused expert clients 
across 49 clinics. Each clinic receives $260 monthly to employ PLHIV for task-sharing 
activities and community outreach. The initiative has resulted in improvements in clinic 
flow, better retention, stronger referral linkages and more efficient teamwork [54]. As 
national programs decentralize HIV care and treatment to the primary level, this type of task 
sharing is essential and should be made a routine component of service delivery.
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Conclusion
The pillars of Treatment 2.0 represent a broad framework to simplify and streamline 
treatment and integrate HIV services into all layers of the health system. The overarching 
goal is to reach universal access to ART, despite declining levels of donor support. For 
adults, this is tenable and in many programs, elements of Treatment 2.0 are already well 
established. For children however, ART scale up has been slow and universal access 
remains elusive. Furthermore, with global attention focused on pediatric HIV prevention, 
and new WHO guidelines setting a high bar for optimal management of HIV-infected 
children, there is a real risk that pediatric treatment scale-up may decline. In this article, we 
propose eight pediatric Treatment 2.0 interventions, which we believe are necessary to 
reverse this trend.
1. Secure the pediatric ARV market through coordinated global purchasing and 
strategic product selection by national programs to minimize market fragmentation, 
maximize volume discounts and increase supply security.
2. Ensure that LPV/r granules are rapidly brought to market once approved as these 
will fill a critical formulation gap for infants. However, in the interim, work with 
other options – including LPV/r syrup and NVP-based FDCs. Increasing the 
momentum of infant ART scale up is critical, and although LPV/r-based therapy is 
ideal, NVP-based therapy is far better than no therapy at all.
3. Promote rapid, high-quality research to better define the risks and benefits of TDF 
as a drug for children and innovate newer drugs and regimens that could truly 
harmonize ART for patients of all ages.
4. Scale up both centralized and PoC infant diagnosis and strengthen the overall 
laboratory system to better serve the needs of children.
5. Emphasize task sharing for pediatric ART and develop rapid and robust plans to 
decentralize services and integrate with adult and maternal programs.
6. Implement routine approaches to testing infants and children in high burden 
settings.
7. Improve information management systems to ensure that children don’t fall 
through the cracks – especially along the PMTCT continuum.
8. Enhancing community participation in the response to pediatric HIV. The active 
role of communities in identifying children early, supporting referral and retention 
into care, ensuring equity in access to services and fighting stigma needs to be 
defined and supported.
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Fig. 1. Patients on antiretroviral therapy (ART) in millions
Source: WHO TUAPR 2011, (pub November 2011) for historical data; WHO/UNAIDS 
Global update on HIV treatment 2013,(pub June 2013) for 2011 and 2012 statistics on 22 
countries within the Global Plan.
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Fig. 2. Expected growth of pediatric antiretroviral therapy (ART) patients
Source: 2009–2011 actual patient numbers provided by WHO TUAPR; 2012 patient 
numbers extrapolated using linear patient growth of WHO/UNAIDS reported 2011 figures 
(Courtesy CHAI).
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Fig. 3. Fragmentation in care provision for selected interventions in a family with one or more 
members living with HIV
ANC, antenatal clinic; ART, antiretroviral therapy; L & D, labor and delivery; MNCH, 
mothers, neonatal and child health.
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Fig. 4. Family centered provision of health services for HIV: a comprehensive and coordinated 
approach addresses the HIV and general health needs of all members of the family
ANC, antenatal clinic; ART, antiretroviral therapy; MNCH, mothers, neonatal and child 
health; STI, sexual transmitted infection.
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